Inhibition of cytokine-induced sh2 protein in nk cells
AssigneeThe Walter and Eliza Hall Institute of Medical Research
InventorsNicholas D. Huntington, Sandra E. Nicholson
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition
Claims11
1-64. (canceled)
A method of obtaining human NK cells, comprising differentiating human pluripotent stem cells into human NK cells, wherein the human NK cells are genetically modified human NK cells in which one or both Cish alleles have been inactivated by a genetic modification.
A method of obtaining human NK cells, comprising differentiating human induced pluripotent stem cells into human NK cells, wherein the human NK cells are genetically modified human NK cells in which both Cish alleles have been inactivated by a genetic modification.
Dependencies are inferred from the claim text.